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SummAry Juvenile systemic lupus erythematosus (JSLE) is a systemic 
autoimmune chronic disease that can affect any part of the body. It is 
characterized by the formation of antibodies against nuclear antigens. 
Vasculitis may be found in SLE, but it scarcely complies with anti-neu-
trophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) crite-
ria. We report five cases of severe JSLE associated with AAV diagnosed 
between 1991 and 2013 in three university-based tertiary care centers. 
The patients (3 girls and 2 boys, aged 12 to 17) presented with a severe 
clinical picture and the following features: cytopenia (n=5), autoimmune 
hepatitis (n=3), lupus nephritis (n=1), pancreatitis (n=1), secondary an-
tiphospholipid syndrome (n=2), impending respiratory failure (n=2), 
and gastrointestinal bleeding (n=1). 
All patients were proteinase 3 (PR3) ANCA positive, while two of them 
were myeloperoxidase (MPO) and PR3 ANCAs positive at the same time. 
They were treated with corticosteroids and immunosuppressive drugs. 
Remission of the disease was achieved in three patients. The course of 
the disease was worsening in two patients and we included rituximab 
(anti-CD20) in therapy. All of our patients presented as the most severe 
SLE patients, who must be diagnosed as soon as possible and treated 
very intensively. Since the comorbidity of JSLE and AAV occurs very 
rarely in children, presentation of such patients, their clinical pictures, 
treatment, and the course of the diseases are experiences that can be 
of great help. 
KEyWordS: systemic lupus erythematosus; ANCAs; ANCA-associated 
vasculitis
IntroduCtIon
Systemic lupus erythematosus (SLE) is a multi-
system autoimmune connective tissue disorder with 
various clinical presentations that can imitate many 
diseases (1,2). Fifteen to twenty percent of SLE cases 
occur before the age of 16. When presenting in child-
hood, SLE is often more severe and usually includes 
the vital organs (3). It is characterized by the presence 
of multiple autoantibodies, including serum antibod-
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ies against nuclear components (ANA), circulating 
immune complexes, and activation of the comple-
ment system. Anti-neutrophil cytoplasmic antibod-
ies (ANCA) can also be detected. It is a group of au-
toantibodies directed against various neutrophil and 
monocyte granule and lysosome constituents. Clini-
cally significant are ANCAs directed to proteinase 3 or 
myeloperoxidase, whereas the importance of other 
ANCAs is unknown (4). ANCAs are strongly associat-
ed with small vessel vasculitis (AAV), which includes 
Wegener’s granulomatosis, microscopic polyangitis 
(MPA), and Churg-Strauss syndrome (CSS) (5). Ac-
cording to studies, approximately 15-20% of adults 
(6) and up to 69% of children with SLE have a positive 
ANCA finding, but without signs of vasculitis (7). It is 
estimated that in 4% of SLE patients clinical signs of 
vasculitis may be found (8). Only five patients diag-
nosed with SLE and AAV have been described in the 
literature. To the best of our knowledge, there is only 
one publication regarding children who suffer from 
both JSLE and AAV. Since the coexistence of JSLE and 
AAV occurs very rarely in children, we report five cas-
es of severe JSLE associated with clinical and labora-
tory signs of AAV.
PAtIEntS And mEthodS
We reviewed the medical records of all patients 
aged 1-18 years who were diagnosed with JSLE (ac-
cording to the revised ACR criteria) (9,10) and ANCA-
associated vasculitis (according to ACR/EULAR cri-
teria) (11,12,13) during the period of 1991-2013 
at the Pediatrics Departments at three university 
tertiary care hospitals (Zagreb, Split, Rijeka). Sera of 
all children were tested for the presence of ANA us-
ing indirect immunoflorescence (IIF) on Hep-2 cells 
(Euroimmun, Lübeck, Germany). Sera positive for IIF 
were then tested by antigen-specific enzyme-linked 
immunosorbent assay – ELISA (Euroimmun, Lübeck, 
Germany). ANCA tests were determined by IIF us-
ing in-house preparations of ethanol – fixed human 
purified neutrophils as cellular substrate. MPO- and 
PR3-ANCA were performed using ELISA (Euroimmun, 
Lübeck, Germany). Positive C-ANCA, P-ANCA serum, 
and negative control were included in every ANCA 
determination. Before we started gathering the data, 




A 12-year-old girl, whose disease started four 
weeks prior to hospitalization, presented with myal-
gia, polyarthralgia, vasculitic palm rash, right palm 
swelling, hepatosplenomegaly, and persistent low-
grade fever (Table 1). The third day after admission 
she became tachydyspnoic and orthopnoic with 
respiratory insufficiency and pale-green skin. In the 
laboratory findings there were severe anemia, leuco-
penia, and markedly increased transaminases, highly 
elevated erythrocyte sedimentation rate (ESR), C 
– reactive protein (CRP), and polyclonal gammopathy 
(Table 2). ANAs were also significantly positive (dsD-
NA, histone, SS-A, SS-B, U1-RNP) with highly elevated 
ANCA (PR3 ANCA) and positive anticardiolipin anti-
bodies (Table 2). MSCT of the abdomen showed an 
enlarged spleen, liver, and retroperitoneal lymphade-
nopathy. We started treatment with pulse corticoste-
roids (three consecutive days), pulse cyclophospha-
mide (6×), and azathioprine, after which the clinical 
picture and laboratory findings became normalized 
with the exception of slight thrombocytopenia. She 
has been in complete remission for five years (Tables 
2 and 3). 
Case 2
This case involved a 14-year-old girl who was di-
agnosed with polyarticular juvenile idiopathic arthri-
tis (JIA) in 2008 and treated with corticosteroids and 
methotrexate at a local hospital. Her first hospitaliza-
tion at the University Hospital, Department of Pedi-
atric Rheumatology and Immunology came three 
years later because of her deteriorating condition, 
when she presented with general distress, severe 
headaches, nausea, and arthralgias. A physical exami-
nation showed radiocarpal, metacarpophalangeal, 
and talocrural edema, swan-neck deformities of the 
fingers and prominent vasculitic rash on the palms 
(Table 1). The laboratory work-up revealed elevated 
ESR, highly elevated transaminases, anemia, throm-
bocytopenia, hypergammaglobulinaemia, low com-
plement with positive ANAs, dsDNA, and histone an-
tibodies, positive PR3 ANCAs, and AGLM (Table 1 and 
2). A liver biopsy showed chronic active hepatitis and 
MR of brain CNS vasculitis. We started treatment with 
corticosteroid pulse therapy (three consecutive days) 
followed by corticosteroids orally and pulse cyclo-
phosphamide therapy (6×). Since there were no clini-
cal or laboratory result improvements, rituximab was 
added into the therapy. The course of her disease was 
later complicated by trombophlebitis and suspected 
deep vein thrombosis of the lower leg. Clinically, this 
girl is much better now, but according to laboratory 
findings, the disease is still somewhat active (Tables 
2 and 3). 
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Case 3
A 14-year-old girl was hospitalized for severe ab-
dominal pain in the upper right quadrant with a fever 
and general distress. She was diagnosed with acute 
pancreatitis (elevation of amylases) and a hepatic le-
sion (elevation of transaminases and bilirubin). A liver 
biopsy specimen indicated signs of highly active chron-
ic hepatitis, and an abdominal multi-slice computer 
tomography (MSCT) showed enlarged lymph nodes 
retroperitoneally. Since lymphoma was suspected, an 
explorative laparotomy was performed. Histology of 
the removed lymph nodes excluded malignancy, con-
firming reactive inflammatory changes. After a lapa-
rotomy was done the general condition of patient was 
aggravated by respiratory failure and a vasculitic rash. 
Laboratory findings showed highly elevated ESR and 
CRP, anemia, and hypergammaglobulinaemia, with 
positive anti-dsDNA, histone, U1RNP antibodies, and 
ANCAs (Table 2). The patient was treated with cortico-
steroids orally followed by pulse cyclophosphamide 
therapy (6×). She responded well and the dose of 
corticosteroids was slowly reduced. Azathioprine and 
hydroxychloroquine were entered into therapy. Today, 
she is in complete clinical and laboratory remission at 
a follow-up of almost four years (Table 2). 
Case 4
A 13-year-old boy was hospitalized three weeks 
after the onset of his disease that presented with fe-
ver, severe headaches, abdominal pain, polyarthral-
gia, and a prominent malar rash on the face, a rash 
on the legs consistent with livedo reticularis, cervi-
cal lymphadenopathy, and fatigue. He had suffered 
from asthma for several years. Laboratory findings 
showed anemia, leucopenia, thrombocytopenia, and 
lower levels of complement with positive ANA (ds-
DNA, histone, SS-A, SS-B, U1-RNP, Smith), ANCA-PR3, 
and anticardiolipin antibodies (Table 2). An Magnetic 
resonance imaging (MRI) of the brain was performed 
because of suspected CNS vasculitis, but the result 
was normal. Corticosteroids and hydroxychloroquine 
were entered into therapy. After two weeks of such 
treatment, proteinuria was observed (total proteins 
were 1.73 g in daily urine). A renal biopsy according 
to the ISN/RPS 2004 classification showed membra-
nous lupus nephritis (class V). Pulse doses of cyclo-
phosphamide (6×) were introduced into therapy. 
After the last pulse of cyclophosphamide, proteinuria 
was again observed (2.5g in daily urine) and we start-
ed with mycophenolate mofetil, but with no success. 
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ANCA: anti-neutrophil cytoplasmic antibodies; CNS: central nervous system; SLE: systemic lupus erythematosus.
table 1. Clinical characteristics of 5 patients with juvenile SLE and ANCA-associated vasculitis 
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Therefore we decided to include rituximab. With that 
treatment proteinuria has been well controlled for 2.5 
years.
Case 5
A 17-year-old boy was hospitalized because of 
evaluation of liver damage that was detected by acci-
dent during the work-up for respiratory infection (pu-
rulent nasal discharge). Seven months prior to hospi-
talization, he noticed blood in the stool several times. 
Three weeks prior to admission, he was fatigued 
and had a loss of appetite. During hospitalization, 
he suffered severe abdominal pain with vomiting 
and gastrointestinal bleeding (Table 1). Laboratory 
work-up showed elevated ESR and transaminases, 
hypergammaglobulinaemia, positive ANA (dsDNA, 
histone), ANCAs (both PR3 and MPO), and AGLM with 
lower levels of complement (Table 2). A liver biopsy 
disclosed autoimmune hepatitis of high activity with 
necrosis. He was treated with corticosteroids and aza-
thioprine. After 3.5 years of follow-up he is clinically 
well, but antibodies are still positive (Table 2). 
dISCuSSIon
We report on five patients with a confirmed diag-
nosis of juvenile SLE and AAV and discuss the disease 
characteristics, treatment modalities, course of the 
disease and available criteria. Descriptions of such 
patients in the literature are scarce, especially in chil-
dren. Searching the literature, we have found only one 
description of such a patient during childhood (14). 
Although the time between the manifestations of 
these two diseases could be more than 10 years (15), 
all our cases had clinical and laboratory features of 
both diseases already present during the initial diag-
nostic assessment. Their overall clinical presentation 
appeared heterogeneous. A similar observation has 
been noted in a study of SLE-AAV overlap syndrome 
in adults (15). Two patients had impending respiratory 
failure; one had renal involvement, one CNS vasculitis, 
and in one the gastrointestinal system was involved. 
Most of the patients described in the literature (15), 
including our cases, had very pronounced respira-
tory manifestations, which leads us to the conclusion 
that the respiratory system may be at a very high risk 
of being affected in this comorbidity. On the other 
table 2. Immunological findings of five patients with juvenile SLE and ANCA-associated vasculitis 





































ANA 1:10240 speckled 1:1600 Homo-genous 1:3200
Homo-
genous 1:3200 neg 1:1600 1:800
Anti ds-DNA 




293 neg 290 105 327 nd 351 nd 360 124
ANCA 1:20480 neg 1:160 neg 1:1280 1:40 1:10240 neg 1:5120 neg
MPO (RU/ml) 
(n.v. < 20) neg neg 14 7 139 nd 6 neg 148 nd
PR3 (RU/ml) 
(n.v. < 20) 86 neg 25 5 25 nd 96 neg 42 nd
IgG (g/l) 
(n.v. 7.0-16.0) 48.22 8.,87 22.01 10.95 73.58 21.87 17.07 3.87 38.28 9.92
IgA (g/l) 
(n.v. 0.7-4.0) <0.05 0.09 0.72 0.46 3.39 2.49 2.68 1.65 2.74 1.74
IgM (g/l) 
(n.v. 0.4-2.3) 2.61 0.66 1.89 0.38 1.51 2.26 1.21 0.22 0.82 0,81
IgE (kIU/L) (n.v. 
< 100)
2532 
kIU/L > 2000 nd nd 393.3 nd 980 190 82.9 29.8
A/G inversion 0.48 1.91 0.91 1.53 0.36 1.02 1.02 1.66 0.7 1.6
ANCA: anti-neutrophil cytoplasmic antibodies; APLS: antiphospolipid syndrome; CNS: central nervous system; SLE: systemic 
lupus erythematosus; y=years.
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hand, low renal involvement in our patients was not 
in accordance with the published literature (14,15). 
It seems that in our pediatric patients the kidneys 
were less affected than in adults with this syndrome. 
The only reported case of a child with SLE-Wegener 
granulomatosis association that we found also had 
significant renal involvement. The gastrointestinal 
system in one of our patients was affected, and it is 
important to note that the Japanese Research Group 
of Intractable Vasculitis, Ministry of Health, Labor, and 
Welfare (MHLW) included gastrointestinal bleeding 
among the diagnostic criteria for a precise diagno-
sis of AAV (16). What was similar in most of our cases 
(four out of five patients) was the presence of a vas-
culitic rash. Vasculitic rash is a characteristic and com-
mon skin finding of small-sized vessel vasculitis and 
has therefore been recognized as a significant sign: 
we found that it is also included in the abovemen-
tioned AAV diagnostic criteria used in Japan. Even 
though vasculitic rash and gastrointestinal bleeding 
are not incorporated into the ACR/EULAR criteria, in 
view of our experience, we suggest that these entities 
can be used as surrogate or additional descriptors in 
cases of suspected small-vessel vasculitis, especially 
in childhood.
Considering the fact that most of our patients had 
another autoimmune or inflammatory disease (JIA, 
autoimmune hepatitis, secondary ALPS, pancreati-
tis) it seems that in patients with this association the 
occurrence of certain autoimmune or inflammatory 
disorders might be increased. Several papers report 
the possible mechanisms involved in the pathogen-
esis of these disorders within the separate SLE or 
AAV diagnoses. Those mechanisms include genetic 
predisposition, vasculitis, immune complex deposi-
tion, vascular intimal thickening and inflammation, 
thromboembolic events, generalized sororities, use 
of immunosuppressive therapy, etc. (17,18). The pres-
ence of some of these autoimmune diseases in such 
patients is partly in line with the literature since cases 
with this association and ALPS have already been de-
scribed (15). We have not found descriptions about 
patients with comorbidity of AAV, SLE, and autoim-
mune hepatitis (AIH), as we did in most of our cases. 
Regarding laboratory findings, the literature states 
that all such patients displayed cytopenia, which is in 
line with our findings (15). Three of our patients had 
thrombocytopenia, three leukopenia, and three ane-
mia. It is also interesting that three of our patients 
had extremely high serum immunoglobulin E (IgE) 
levels (Table 2), but we were not able to find similar 
reports. One of those cases had asthma, but others 
did not have any evident reason that could lead to an 
elevation of IgE. It might be very interesting to test 
IgE in severe SLE patients with concomitant vasculi-
tis to see if there is any connection. Laboratory tests 
also revealed high titer of ANA, anti-dsDNA and anti-
histone, and highly positive ANCA in all patients. It is 
important to consider the possibility of false positive 
ANCA due to the high titer of ANA, leading to a false 
diagnosis of the comorbidity of SLE and AAV. The 
literature reports that ANCA positivity, when tested 
by IIF in SLE patients, is higher than when tested by 
ELISA, because of the presence of non-PR3, non-MPO 
ANCA and the difficulty in differentiating p-ANCA 
from ANA by IIF (19). According to the International 
Consensus Statement on Testing and Reporting of 
ANCA from 1999, serum samples containing ANCA 





































ESR (mm/h) 93 29 26 6 124 21 55 17 30 21
CRP (mg/L) 25.5 <0.3 2.5 0.5 21.2 2.0 0.4 1.0 0.2 0.1
Hgb (g/L) 95 122 112 115 98 123 97 139 143 141
Hct (L/L) 0.28 0.42 0.343 0.35 0.30 0.38 0.28 0.397 0.426 0.41
WBC x109/L 3.0 3.65 5.7 3.3 10.2 4.6 3.5 7.63 7.30 7.7
PLT x109/L 274 162 137 115 477 274 121 313 326 203
AST (U/L) 663 25 1194 29 482 37 59 19 473 18
ALT (U/L) 352 21 602 22 437 27 46 27 1009 17
GGT (U/L) 96 16 63 18 228 63 18 26 312 21
AST: aspartate aminotransferase; ALT: alanin aminotransferase; GGT: gama glutamil transferase; Hbg: hemoglobin; Htc: 
hematocrit; PLT: platelet; WBC: white blood cells
table 3. Laboratory findings of five patients with juvenile SLE and AAV
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by IIF should be tested in ELISAs for PR3-ANCA and 
MPO-ANCA. Moreover, all serum samples should be 
tested in ELISAs for PR3-ANCA and MPO-ANCA, as we 
did in all our cases (20).
We should also mention that some authors no-
ticed a positive correlation between hypergamma-
globulinemia and c-ANCA titers. They hypothesized 
that polyclonal B cell proliferation may lead to the 
presence of c-ANCA antibodies (21) and false positive 
results. Hypergammaglobulinemia was found in all 
our patients but we cannot say that there is positive 
correlation between the level of hypergammaglobu-
linaemia and, in our case, the level of p-ANCA titres. 
There are contradictory data in the literature re-
garding positive correlations between ANCA antibod-
ies and specific symptoms. While some authors state 
that there is a positive correlation between ANCA and 
a specific symptom (such as serositis, livedo reticu-
laris, venous thrombosis, and arthritis) and with dis-
ease activity of SLE (22-24), other authors have found 
that there is no association either between ANCA and 
specific organ involvement or between the level of 
ANCA and disease activity (25,26). It is important to 
point out that most of our patients presented with se-
vere initial symptoms and with highly positive ANCA 
during that period. According to our results, the level 
of ANCA could be a marker of disease activity.
Disease treatment was similar to the treatment 
recommended in available literature (14,15). Cortico-
steroids together with immunosuppressives (pulses 
of cyclophosphamide) were used as an induction 
therapy. In two patients who did not respond well 
we administered rituximab (anti-CD20), which has 
shown satisfactory results so far.
Since there were very few patients described with 
this overlap syndrome and they were followed for 
quite a short period, we can say that the course of 
disease is actually unknown. Two patients died (one 
of them was child), and the others are in remission 
(14,15). We followed our patients for almost five years. 
Three of them are in remission and other two have 
satisfactory control of the disease.
ConCLuSIon
Even though there is very small amount of infor-
mation in the literature, it seems that the comorbidity 
of juvenile SLE and ANCA-associated vasculitis is not 
as rare as we expected, and that doctors should be 
aware of it. All of our patients presented as the most 
severe patients with both SLE and AAV clinical and 
biological features, who must be diagnosed as soon 
as possible and treated very intensively. In this way, 
it is definitely possible to prolong survival, improve 
the quality of life, develop novel therapies, and de-
termine the best approach for providing care to this 
complex group of patients.
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